Femoral Artery
Trial Data Demonstrates Bard LIFESTENT(R) Vascular Stent Is Superior to Angioplasty for Lesions in Superficial Femoral Artery and Proximal Popliteal Artery
Published in Drug Week, July 2nd, 2010
C. R. Bard, Inc. announced the publication of RESILIENT trial results by Circulation: Cardiovascular Interventions showing the Bard LIFESTENT® Vascular Stent improved patency and reduced revascularization rates in patients with moderate-length lesions in the superficial femoral artery (SFA) and proximal popliteal artery compared to patients treated with percutaneous transluminal angioplasty (PTA).
To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/bard/44623/
The LIFESTENT® Vascular Stent is the only stent approved by the U.S. Food and Drug Administration and commercially available...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2010-07-02)
More Articles from Drug Week
- Antibiotics
Accelr8 Announces Industry Agreement for Technology Evaluation Project - Adenosine Therapy
Acupuncture's molecular effects pinned down - Analgesics
Colombian Trafficker with Links to Mexican and Colombian Cartels Extradited from Mexico to the U.S. - Cancer Therapy
Data on cancer therapy discussed by researchers at Brussels Free University - Drug Development
Data on drug development published by L.Q. Cong and colleagues - Propylamines
Data on propylamines reported by researchers at Charite University - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
